Sawai Group Holdings Co., Ltd. (4887.T)
JPY 1905.0
(0.53%)
JPY 1905.0
(0.53%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 35.43 Billion JPY | -22.38% |
| 2022 | 45.64 Billion JPY | -55.48% |
| 2021 | 102.54 Billion JPY | 90.52% |
| 2020 | 53.82 Billion JPY | 14.85% |
| 2019 | 46.86 Billion JPY | -4.46% |
| 2018 | 49.05 Billion JPY | 14.02% |
| 2017 | 43.01 Billion JPY | 56.01% |
| 2016 | 27.57 Billion JPY | -0.18% |
| 2015 | 27.62 Billion JPY | 10.22% |
| 2014 | 25.06 Billion JPY | 11.33% |
| 2013 | 22.51 Billion JPY | 11.86% |
| 2012 | 20.12 Billion JPY | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 7.89 Billion JPY | -27.94% |
| 2023 FY | 35.43 Billion JPY | -22.38% |
| 2023 Q3 | 8.19 Billion JPY | -25.66% |
| 2023 Q4 | 10.96 Billion JPY | 33.76% |
| 2023 Q1 | 11.55 Billion JPY | -2.64% |
| 2023 Q2 | 11.02 Billion JPY | -4.6% |
| 2022 Q4 | 11.86 Billion JPY | -1.93% |
| 2022 Q3 | 12.1 Billion JPY | 8.75% |
| 2022 Q2 | 11.12 Billion JPY | 5.38% |
| 2022 Q1 | 10.55 Billion JPY | -85.33% |
| 2022 FY | 45.64 Billion JPY | -55.48% |
| 2021 Q4 | 71.98 Billion JPY | 747.74% |
| 2021 Q1 | 10.22 Billion JPY | -48.02% |
| 2021 FY | 102.54 Billion JPY | 90.52% |
| 2021 Q3 | 8.49 Billion JPY | -28.29% |
| 2021 Q2 | 11.84 Billion JPY | 15.78% |
| 2020 Q3 | 11.91 Billion JPY | 5.27% |
| 2020 Q1 | 10.74 Billion JPY | -20.75% |
| 2020 FY | 53.82 Billion JPY | 14.85% |
| 2020 Q4 | 19.67 Billion JPY | 65.17% |
| 2020 Q2 | 11.31 Billion JPY | 5.32% |
| 2019 Q4 | 13.55 Billion JPY | 20.83% |
| 2019 Q3 | 11.21 Billion JPY | 2.46% |
| 2019 Q2 | 10.94 Billion JPY | -0.62% |
| 2019 FY | 46.86 Billion JPY | -4.46% |
| 2019 Q1 | 11.01 Billion JPY | -28.35% |
| 2018 Q2 | 11.58 Billion JPY | 4.49% |
| 2018 Q3 | 10.98 Billion JPY | -5.17% |
| 2018 Q1 | 11.08 Billion JPY | -38.86% |
| 2018 FY | 49.05 Billion JPY | 14.02% |
| 2018 Q4 | 15.37 Billion JPY | 39.99% |
| 2017 FY | 43.01 Billion JPY | 56.01% |
| 2017 Q1 | 7.58 Billion JPY | -19.82% |
| 2017 Q4 | 18.13 Billion JPY | 37.77% |
| 2017 Q3 | 13.16 Billion JPY | 38.95% |
| 2017 Q2 | 9.47 Billion JPY | 24.85% |
| 2016 Q2 | 7.53 Billion JPY | -3.0% |
| 2016 Q4 | 9.46 Billion JPY | 28.9% |
| 2016 Q1 | 7.77 Billion JPY | -6.03% |
| 2016 Q3 | 7.34 Billion JPY | -2.64% |
| 2016 FY | 27.57 Billion JPY | -0.18% |
| 2015 FY | 27.62 Billion JPY | 10.22% |
| 2015 Q4 | 8.27 Billion JPY | 19.26% |
| 2015 Q3 | 6.93 Billion JPY | -6.74% |
| 2015 Q2 | 7.43 Billion JPY | 31.96% |
| 2015 Q1 | 5.63 Billion JPY | -20.03% |
| 2014 Q4 | 7.04 Billion JPY | 14.22% |
| 2014 Q3 | 6.16 Billion JPY | 6.55% |
| 2014 Q2 | 5.79 Billion JPY | -4.41% |
| 2014 Q1 | 6.05 Billion JPY | -10.11% |
| 2014 FY | 25.06 Billion JPY | 11.33% |
| 2013 Q2 | 5.43 Billion JPY | 8.41% |
| 2013 Q1 | 5.01 Billion JPY | -11.95% |
| 2013 Q4 | 6.73 Billion JPY | 26.7% |
| 2013 FY | 22.51 Billion JPY | 11.86% |
| 2013 Q3 | 5.31 Billion JPY | -2.22% |
| 2012 Q4 | 5.69 Billion JPY | 31.75% |
| 2012 Q2 | 5.13 Billion JPY | 0.0% |
| 2012 FY | 20.12 Billion JPY | 0.0% |
| 2012 Q3 | 4.32 Billion JPY | -15.79% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 43.63 Billion JPY | 18.804% |
| Takeda Pharmaceutical Company Limited | 2618.18 Billion JPY | 98.647% |
| Sumitomo Pharma Co., Ltd. | 542.17 Billion JPY | 93.465% |
| Shionogi & Co., Ltd. | 197.62 Billion JPY | 82.071% |
| Wakamoto Pharmaceutical Co.,Ltd. | 3.73 Billion JPY | -848.33% |
| Nippon Shinyaku Co., Ltd. | 65.63 Billion JPY | 46.012% |
| Kaken Pharmaceutical Co., Ltd. | 29.02 Billion JPY | -22.073% |
| Eisai Co., Ltd. | 533.01 Billion JPY | 93.352% |
| Morishita Jintan Co., Ltd. | 5.28 Billion JPY | -570.825% |
| Hisamitsu Pharmaceutical Co., Inc. | 65.8 Billion JPY | 46.154% |
| Mochida Pharmaceutical Co., Ltd. | 46.26 Billion JPY | 23.416% |
| Fuso Pharmaceutical Industries,Ltd. | 11.55 Billion JPY | -206.7% |
| Nippon Chemiphar Co., Ltd. | 8.23 Billion JPY | -330.43% |
| Tsumura & Co. | 48.8 Billion JPY | 27.391% |
| Kissei Pharmaceutical Co., Ltd. | 33.32 Billion JPY | -6.329% |
| Torii Pharmaceutical Co., Ltd. | 19.53 Billion JPY | -81.364% |
| Towa Pharmaceutical Co., Ltd. | 63.73 Billion JPY | 44.407% |
| Fuji Pharma Co., Ltd. | 12.65 Billion JPY | -179.948% |
| Zeria Pharmaceutical Co., Ltd. | 40.46 Billion JPY | 12.435% |
| KYORIN Holdings, Inc. | 45.39 Billion JPY | 21.945% |
| Taiko Pharmaceutical Co.,Ltd. | 4.15 Billion JPY | -752.369% |
| Daito Pharmaceutical Co.,Ltd. | 5.94 Billion JPY | -496.013% |
| SymBio Pharmaceuticals Limited | 5.22 Billion JPY | -578.445% |
| MedRx Co., Ltd | 959 Million JPY | -3594.786% |
| Mizuho Medy Co.,Ltd. | 2.87 Billion JPY | -1132.997% |
| Solasia Pharma K.K. | 1.47 Billion JPY | -2300.61% |
| Modalis Therapeutics Corporation | 2.37 Billion JPY | -1394.644% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 24.16 Billion JPY | -46.629% |
| Cyfuse Biomedical K.K. | 735.18 Million JPY | -4719.629% |
| Toho Holdings Co., Ltd. | 99.81 Billion JPY | 64.502% |
| Koa Shoji Holdings Co.,Ltd. | 2.25 Billion JPY | -1469.716% |